Health ProductsDear Healthcare Professional Letter

Health Canada Endorsed Important Safety Information Regarding Avandamet, Avandia, Coreg, Paxil, Paxil CR and Relafen – GlaxoSmithKline Inc. – For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

 
[Text of letter begins]

Health Canada Endorsed Important Safety Information Regarding Avandamet®, Avandia®, Coreg®, Paxil®, Paxil CRTM, and Relafen®

GlaxoSmithKline
7333 Mississauga Road North
Mississauga, Ontario
Canada L5N 6L4

April 15, 2005

Subject: Products Manufactured at GSK's Cidra, Puerto Rico Facility

Dear Health Care Professional,

GlaxoSmithKline Inc. (GSK), following discussions with Health Canada, would like to advise you of findings from inspections at GSK's manufacturing plant in Cidra, Puerto Rico. It is important to note these findings present an extremely low risk to patients and patients should be advised to continue to take these medications as directed. Two primary issues have been identified:

1. Avandamet and Paxil CR Tablets

Inspection by the US Food and Drug Administration has identified manufacturing issues with Paxil CR (paroxetine hydrochloride controlled release tablets) and Avandamet (rosiglitazone maleate/metformin hydrochloride) tablets. One of the findings was that a very small number of Paxil CR tablets could split. Although all products have been sorted and split tablets have been removed, there is a remote possibility that patients could receive a portion of a tablet that lacks active ingredient, or alternatively a portion that contains active ingredient and does not have the intended controlled-release effect. Another finding was that some Avandamet tablets may not have a uniform amount of rosiglitazone, one of the active ingredients in this product.

GSK and Health Canada do not believe these findings pose a significant health risk. GSK has performed additional testing on these products, and along with Health Canada are taking ongoing measures to monitor quality as they are made available in Canada.

2. Potential for Stray Tablets in Bottles or Blister Packs of Avandamet, Avandia, Coreg, Paxil, Paxil CR and Relafen

There is a very remote possibility that bottles or blister packs of Avandamet, Avandia (rosiglitazone maleate), Coreg (carvedilol), Paxil (paroxetine hydrochloride), Paxil CR or Relafen (nabumetone) may contain a stray tablet of another medication. GSK wants to emphasize that in Canada, there have been no reported incidents of manufacturing issues causing stray tablets of another medication to be found in a bottle or blister pack of the above listed products. However, if a patient were to ingest a stray tablet of an unintended medication, there is a possibility this could cause an adverse reaction. Most of these reactions should be mild and transient. However, there is the possibility a more serious reaction can occur. For example, if an asthmatic patient were to receive a dose of Coreg, severe bronchospasm could occur.

Therefore, as an added precaution, until further notice, GSK asks all pharmacies that use automatic dispensers (counting machines) to either manually dispense or visually inspect these products (see table below) before providing them to their patients. There are significant differences in colour and shape between these products and patients should be advised to check the appearance of their medications before taking them and immediately contact their pharmacist and/or physician if they notice any differences.

In the unlikely event that a pharmacist or any pharmacy personnel should discover a tablet of a different shape, size or colour than the medication being dispensed, he or she should contact the Customer Service Department of GSK at 1-800-387-7374 immediately.

Product
Product Strength DIN
Avandamet Tablets 1 mg/500 mg 02247085
Avandamet Tablets 2 mg/1000 mg 02248440
Avandamet Tablets 2 mg/500 mg 02247086
Avandamet Tablets 4 mg/1000 mg 02248441
Avandamet Tablets 4 mg/500 mg 02247087
Avandia Tablets 2 mg 02241112
Avandia Tablets 4 mg 02241113
Avandia Tablets 8 mg 02241114
Coreg Tablets 3,125 mg 02229650
Coreg Tablets 6,25 mg 02229651
Coreg Tablets 12,5 mg 02229652
Coreg Tablets 25 mg 02229653
Paxil Tablets 10 mg 02027887
Paxil Tablets 20 mg 01940481
Paxil Tablets 30 mg 01940473
Paxil CR Tablets 12,5 mg 02248503
Paxil CR Tablets 25 mg 02248504
Relafen Tablets 500 mg 02083531
Relafen Tablets 750 mg 02083558

Please be assured that GSK is working with Health Canada to resolve these issues as quickly as possible. GSK remains committed to product quality and patient safety, and we regret any inconvenience this temporary situation may cause. Should you have any further questions, please contact GSK Customer Service at 1-800-387-7374.

The identification, characterization and management of drug-related adverse events are dependent on the active participation of health-care professionals in adverse drug reaction reporting programs. Healthcare professionals are asked to report any suspected adverse reactions in patients receiving Avandamet, Avandia, Coreg, Paxil, Paxil CR and Relafen directly to GSK or Health Canada at the following addresses:

GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Tel: 1-800-387-7374

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.
Drug Compliance Verification & Investigation Unit
DCVIU_UVCEM@hc-sc.gc.ca
Tel/Tél: (613) 941-3967
Fax/Télé: (613) 952-9805

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

Sincerely,

original signed by

Dr. John A Dillon, MB, BCh, MFPM
Vice-President, Research & Development and Chief Medical Officer
GlaxoSmithKline Inc.

[Text of letter ends]
 
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime